ArticleFrontiers in oncology2024
Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Prognostic significance of pretreatment systemic immune-inflammation index (SII) in patients with cervical cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in colorectal cancer: a meta-analysis.Annals of medicine · 2025Pooled it
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Pan-immune-inflammation value in lung cancer: prognostic significance and implications for therapeutic guidance - a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in non-small cell lung cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic role of fibrinogen-to-albumin ratio in patients with gynecological cancers: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Association between pan-immune-inflammation value and prognosis in lung cancer patients: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Multidimensional modeling and stratification of nutritional risk in non-small cell lung cancer based on artificial intelligence-derived CT body composition phenotypes.Frontiers in nutrition · 2026Article
- Fibrinogen in extracellular matrix remodeling: functional switching, source heterogeneity, and biomaterial translation.Frontiers in cell and developmental biology · 2026Review
- The prognostic importance of the pan-immune-inflammation value (PIV) in lung cancer: a systematic review and meta-analysis.Translational lung cancer research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The inflammatory response and the nutritional status are associated with overall survival (OS) in patients with non-small cell lung cancer (NSCLC), but it is unclear which biomarkers are better suited to predict prognosis. This study sought to determine which of the commonly existing inflammatory and nutritional indicators best predicted the OS. Methods: This study included 15 compound indicators based on inflammation or nutrition, with cutoff points obtained through the receiver operating characteristic (ROC) curve. Univariate and multivariate Cox proportional risk models were used to evaluate the relationship between these predictors and OS. Kaplan-Meier curves were used for survival analysis, and log-rank tests were used to compare differences between groups. The C-index was calculated to evaluate the predictive ability of the different indicators. Results: The study included 899 patients with NSCLC. In the univariate analysis, all 15 measures were significantly associated with the OS of patients (all Conclusion: For all patients with NSCLC, the prognostic power of FAR was superior to that of other inflammatory and nutritional indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.